Convergence Investment Partners’s Neurocrine Biosciences NBIX Stock Holding History

Convergence Investment Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.47M	Buy	+32,433	New	+$4.81M	0.52%	65

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Convergence Investment Partners's NBIX Position: Q2 2026 in Review

Convergence Investment Partners opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 32,433 shares worth $5.47M. The stake represents 0.52% of the portfolio and ranks #65 among its holdings.

771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Convergence Investment Partners held 32,433 shares of Neurocrine Biosciences worth $5.47M as of Q2 2026.
Neurocrine Biosciences was a new Convergence Investment Partners position in Q2 2026.
Neurocrine Biosciences made up 0.52% of Convergence Investment Partners's portfolio in Q2 2026, its #65 holding.
771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Convergence Investment Partners's 13F filing for Q2 2026, filed 31 Jul 2026.